Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 10, 2013, Pages

  Asirvatham Jeyaraj, Ninitha ^a   King, Andrew J ^a   Northcott, Carrie A ^a   Madan, Shivanshu ^a   Fink, Gregory D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Angiotensin II; Cyclooxygenase; Hypertension; Salt; Sympathetic

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ANGIOTENSIN II; CYCLOOXYGENASE 1; HEXAMETHONIUM; HYPERTENSIVE FACTOR; KETOPROFEN; NIMESULIDE; NORADRENALIN; PROSTANOID; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEPRESSOR RESPONSE; DISEASE COURSE; GANGLION BLOCK; HYPERTENSION; MALE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; SALT INTAKE;

ANGIOTENSIN II; CYCLOOXYGENASE; HYPERTENSION; SALT; SYMPATHETIC;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; GANGLIONIC BLOCKERS; HYPERTENSION; KETOPROFEN; MALE; MEMBRANE PROTEINS; NOREPINEPHRINE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE, DIETARY; SULFONAMIDES; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 84887571903     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00245.2013     Document Type: Article

References (44)

1. Anneken JH, Cunningham JI, Collins SA, Yamamoto BK, Gudelsky GA. MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase. J Neuroimmune Pharmacol 8: 58-65, 2013.
2. Araujo M, Welch WJ. Tubuloglomerular feedback is decreased in COX-1 knockout mice after chronic angiotensin II infusion. Am J Physiol Renal Physiol 298: F1059-F1063, 2010.
3. Cao X, Peterson JR, Wang G, Anrather J, Young CN, Guruju MR, Burmeister MA, Iadecola C, Davisson RL. Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain. Hypertension 59: 869-876, 2012.
4. Cox BF, Bishop VS. Neural and humoral mechanisms of angiotensindependent hypertension. Am J Physiol Heart Circ Physiol 261: H1284-H1291, 1991.
5. Davis PA, Mussap M, Pagnin E, Bertipaglia L, Savica V, Semplicini A, Calo LA. Early markers of inflammation in a high angiotensin II state- results of studies in Bartter's/Gitelman's syndromes. Nephrol Dial Transplant 21: 1697-1701, 2006.
6. Eisenhofer G. Sympathetic nerve function-assessment by radioisotope dilution analysis. Clin Auton Res 15: 264-283, 2005.
7. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121-128, 2006.
8. Fierro-Carrion GA, Ram CV. Nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure. Am J Cardiol 80: 775-776, 1997.
9. Fink GD. Long-term sympatho-excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Clin Exp Pharmacol Physiol 24: 91-95, 1997.
10. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 167: 394-399, 2007.
11. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 46: 500-507, 2005.
12. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 17: 626-635, 1991.
13. Gu B, Desjardins P, Butterworth RF. Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide. Metab Brain Dis 23: 175-187, 2008.
14. Inoue M, Crofton JT, Share L. Interactions between the brain reninangiotensin system and brain prostanoids in the control of vasopressin secretion. Exp Brain Res 83: 131-136, 1990.
15. Jia Z, Zhang A, Zhang H, Dong Z, Yang T. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 99: 1243-1251, 2006.
16. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121: 289-300, 1994.
17. Keeton TK, Biediger AM. The measurement of norepinephrine clearance and spillover rate into plasma in conscious spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 338: 350-360, 1988.
18. King AJ, Novotny M, Swain GM, Fink GD. Whole body norepinephrine kinetics in ANG II-salt hypertension in the rat. Am J Physiol Regul Integr Comp Physiol 294: R1262-R1267, 2008.
19. King AJ, Osborn JW, Fink GD. Splanchnic circulation is a critical neural target in angiotensin II salt hypertension in rats. Hypertension 50: 547-556, 2007.
20. Kuroki MT, Guzman PA, Fink GD, Osborn JW. Time-dependent changes in autonomic control of splanchnic vascular resistance and heart rate in ANG II-salt hypertension. Am J Physiol Heart Circ Physiol 302: H763-H769, 2012.
21. Lau YE, Galligan JJ, Kreulen DL, Fink GD. Activation of ETB receptors increases superoxide levels in sympathetic ganglia in vivo. Am J Physiol Regul Integr Comp Physiol 290: R90-R95, 2006.
22. Luft FC, Wilcox CS, Unger T, Kuhn R, Demmert G, Rohmeiss P, Ganten D, Sterzel RB. Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension 14: 396-403, 1989.
23. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, Alvarez Y, Aguado A, Perez-Giron JV, Garcia-Redondo L, Esteban V, Redondo JM, Alonso MJ, Briones AM, Salaices M. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 18: 51-65, 2013.
24. McGiff JC, Crowshaw K, Terragno NA, Lonigro AJ. Release of a prostaglandin-like substance into renal venous blood in response to angiotensin II. Circ Res 27: 121-130, 1970.
25. Mistry M, Nasjletti A. Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension. Hypertension 11: 758-762, 1988.
26. Okuno T, Lindheimer MD, Oparil S. Central effects of prostaglandin E2 on blood pressure and plasma renin activity in rats. Role of the sympathoadrenal system and vasopressin. Hypertension 4: 809-816, 1982.
27. Osborn JL. Relation between sodium intake, renal function, and the regulation of arterial pressure. Hypertension 17: I91-I96, 1991.
28. Osborn JW, Fink GD, Sved AF, Toney GM, Raizada MK. Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. Curr Hypertens Rep 9: 228-235, 2007.
29. Parsadaniantz SM, Lebeau A, Duval P, Grimaldi B, Terlain B, Kerdelhue B. Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol 12: 766-773, 2000.
30. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153: 477-484, 1993.
31. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 110: 61-69, 2002.
32. Quilley J. COX-2 and angiotensin II-induced hypertension and oxidative stress. Am J Hypertens 24: 1188, 2011.
33. Sato Y, Ogata E, Fujita T. Role of chloride in angiotensin II-induced salt-sensitive hypertension. Hypertension 18: 622-629, 1991.
34. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387-437, 2004.
35. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160, 1996.
36. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49: 153-179, 1991.
37. Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 111: 5821-5865, 2011.
38. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res 50 Suppl: S423-S428, 2009.
39. Touw KB, Haywood JR, Shaffer RA, Brody MJ. Contribution of the sympathetic nervous system to vascular resistance in conscious young and adult spontaneously hypertensive rats. Hypertension 2: 408-418, 1980.
40. Von der Weid PY, Hollenberg MD, Fiorucci S, Wallace JL. Aspirintriggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 110: 1320-1325, 2004.
41. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12: 205S-213S, 1999.
42. Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4: 160-166, 2002.
43. Wu R, Duchemin S, Laplante MA, De Champlain J, Girouard H. Cyclo-oxygenase-2 knockout genotype in mice is associated with blunted angiotensin II-induced oxidative stress and hypertension. Am J Hypertens 24: 1239-1244.
44. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 95: 210-216, 2004.